Eli Lilly Q2 FY26 EPS rises 26% to $7.94; revenue increases 48% to $23 billion
Reuters2026/08/05 10:48- Eli Lilly Q2 2026 revenue rose 48% to USD 23 billion, while GAAP EPS climbed 26% to USD 7.94.
- GAAP net income increased 25% to USD 7.1 billion, with results including USD 3.03 per share of acquired IPR&D charges.
- Non-GAAP EPS increased 33% to USD 8.38, despite USD 3.03 per share of acquired IPR&D charges.
- Raised 2026 revenue guidance to USD 85-87 billion; updated non-GAAP EPS outlook to USD 35.5-36.5.
- CEO David Ricks cited momentum, new manufacturing capacity coming online, pipeline additions, and plans to file retatrutide obesity BLA in Q1 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Japanese Yen consolidates near August highs vs USD as hawkish BoJ, Fed bets clash
The 10-year U.S. Treasury yield climbs to 4.8%, erasing the dividend advantage of utility stocks; the sector’s rebound depends on interest rate stabilization rather than technical signals.
As U.S. Treasury yields continue to climb, the American utilities sector is experiencing a significant pullback—a rise in yields not only erodes the relative appeal of the sector’s dividends but also raises financing costs for the most capital-intensive industries within this market.
Euro holds gains above 1.1600 despite robust US jobs data, traders eye ECB rate decision
Crypto prices
More
